Table 2. Univariate and multivariate analysis of overall survival in patients with metastatic nasopharyngeal carcinoma patients (unmatched data).
| Variables | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| Sex | 0.094 | ||||
| Female vs. male | 0.70 (0.46–1.06) | ||||
| Age, years | 0.056 | ||||
| >50 vs. ≤50 | 1.33 (0.99–1.79) | ||||
| T classification | |||||
| T1 | 1 | ||||
| T2 | 0.89 (0.51–1.54) | 0.666 | |||
| T3 | 1.14 (0.69–1.87) | 0.616 | |||
| T4 | 1.11 (0.66–1.85) | 0.695 | |||
| N classification | 0.017 | ||||
| N0 | 1 | ||||
| N1 | 0.86 (0.12–6.41) | 0.881 | |||
| N2 | 1.16 (0.52–1.22) | 0.886 | |||
| N3 | 1.69 (0.24–12.15) | 0.602 | |||
| Histology | |||||
| I | 1 | ||||
| II | 0.52 (0.25–1.01) | 0.053 | |||
| III | 0.67 (0.17–2.69) | 0.567 | |||
| ECOG | 0.08 | ||||
| 1 vs. 0 | 1.41 (0.95–2.10) | ||||
| IMRT | <0.001 | <0.001 | |||
| Yes vs. no | 0.49 (0.36–0.66) | 0.53 (0.39–0.73) | |||
| SII | <0.001 | 0.001 | |||
| ≥930 vs. <930 | 2.04 (1.47–2.82) | 1.75 (1.22–2.52) | |||
ECOG, Eastern Cooperative Oncology Group performance; IMRT, intensity modulated radiotherapy; HR, hazard ratio; CI, confidence interval. SII, systemic immune-inflammation index.